M. Kulyk & Associates LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

M. Kulyk & Associates LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,159 shares of the biopharmaceutical company's stock, valued at approximately $1,538,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Ellerson Group Inc. ADV lifted its holdings in Regeneron Pharmaceuticals by 0.9% in the fourth quarter. Ellerson Group Inc. ADV now owns 6,920 shares of the biopharmaceutical company's stock worth $4,929,000 after acquiring an additional 59 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Schaper Benz & Wise Investment Counsel Inc. WI boosted its position in Regeneron Pharmaceuticals by 6.7% during the 4th quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 19,334 shares of the biopharmaceutical company's stock valued at $13,772,000 after purchasing an additional 1,220 shares during the period. Personal CFO Solutions LLC grew its stake in Regeneron Pharmaceuticals by 230.1% during the 4th quarter. Personal CFO Solutions LLC now owns 1,852 shares of the biopharmaceutical company's stock worth $1,319,000 after buying an additional 1,291 shares during the last quarter. Finally, Atlantic Union Bankshares Corp increased its position in Regeneron Pharmaceuticals by 76.3% in the fourth quarter. Atlantic Union Bankshares Corp now owns 3,996 shares of the biopharmaceutical company's stock worth $2,846,000 after buying an additional 1,729 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several equities analysts have recently commented on REGN shares. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 3.4 %

Shares of Regeneron Pharmaceuticals stock traded down $25.38 on Tuesday, reaching $719.45. 776,669 shares of the company were exchanged, compared to its average volume of 619,233. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $78.65 billion, a price-to-earnings ratio of 18.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average price of $696.96 and a 200-day moving average price of $845.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.